Drug Profile
Amlodipine/rosuvastatin - GSK
Alternative Names: GSK-3074477; Rosuvastatin/amlodipineLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Amines; Antihyperlipidaemics; Antihypertensives; Carboxylic acids; Chlorobenzenes; Dihydropyridines; Esters; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 01 Jul 2014 GlaxoSmithKline completes a phase I trial in Hypertension (In volunteers) in Singapore (NCT02075619)
- 01 Mar 2014 Phase-I clinical trials in Hypertension (In volunteers) in Singapore (PO) (NCT02075619)
- 27 Feb 2014 Preclinical trials in Hypertension in United Kingdom (PO)